Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial-Reference-Cited by-同舟云学术

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Published:2013-03-18 Issue:4 Volume:28 Page:746-752
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Brown Jacques P¹,Roux Christian²,Törring Ove³,Ho Pei‐Ran⁴,Beck Jensen Jens‐Erik⁵,Gilchrist Nigel⁶,Recknor Christopher⁷,Austin Matt⁴,Wang Andrea⁴,Grauer Andreas⁴,Wagman Rachel B⁴

Affiliation:

1. Centre Hospitalier Universitaire de Québec–Centre Hospitalier de l'Université Laval (CHUQ‐CHUL) Research Centre, Québec, Québec, Canada

2. Paris Descartes University, Cochin Hospital, Assistance Publique–Hôpitaux de Paris (AP‐HP), Paris, France

3. Karolinska Institutet, Södersjukhuset, Stockholm, Sweden

4. Amgen Inc., Thousand Oaks, CA, USA

5. Hvidovre University Hospital, Hvidovre, Denmark

6. Canterbury Geriatric Medical Research Trust, Christchurch, New Zealand

7. United Osteoporosis Centers, Gainesville, GA, USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism